Guardant Health Investor Presentation

The challenges of detecting residual disease using cell-free DNA with high sensitivity and high specificity Detection Challenges Genomic Signatures Sensitivity Genomic signatures alone max out TUMOR + Epigenomic Signatures MICRO- ENVIRONMENT at-50% sensitivity for early cancer Specificity Non-tumor sources of biological noise, such as CHIP, can increase difficulty of highly specific detection Using prior knowledge of tumor tissue to filter out such noise is clinically challenging 20 GUARDANT™

View entire presentation